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Osteoarthritis (OA) is a degenerative disease that affects various tissues surrounding joints such as articular cartilage, subchondral
bone, synovial membrane, and ligaments. No therapy is currently available to completely prevent the initiation or progression of
the disease partly due to poor understanding of the mechanisms of the disease pathology. Cartilage is the main tissue afflicted by
OA, and chondrocytes, the sole cellular component in the tissue, actively participate in the degeneration process. Multiple factors
affect the development and progression of OA including inflammation that is sustained during the progression of the disease and
alteration in biomechanical conditions due to wear and tear or trauma in cartilage. During the progression of OA, extracellular
matrix (ECM) of cartilage is actively remodeled by chondrocytes under inflammatory conditions. This alteration of ECM, in turn,
changes the biomechanical environment of chondrocytes, which further drives the progression of the disease in the presence of
inflammation. The changes in ECM composition and structure also prevent participation of mesenchymal stem cells in the repair
process by inhibiting their chondrogenic differentiation. This review focuses on how inflammation-induced ECM remodeling
disturbs cellular activities to prevent self-regeneration of cartilage in the pathology of OA.
1. Introduction
Osteoarthritis (OA) is a debilitating disease, which primarily
affects joints, especially load-bearing areas such as hips and
knees. It is characterized by pain and degenerative changes
in the tissues surrounding those areas. There are no current
therapieswhich can completely prevent the progression of the
disease. Some of themain factors that drive the progression of
OA are chronic inflammation and gradual structural changes
within the joint tissues [1]. Unlike the general concept of OA
being a degenerative disease, the remodeling processes are
highly active throughout each stage of the disease [2]. During
the active remodeling, however, the quality of extracellular
matrix (ECM) is compromised due to the quick turnover rate
and atypical composition of the newly synthesized ECMs [3].
Among many factors, inflammatory cytokines and proteases
are main contributors which mediate the changes in the
quality of ECM [2]. As a consequence of the microenviron-
mental changes, the altered ECM synthesis in the presence of
inflammation, in turn, further disturbs the functions of the
cells.Therefore, there is a constant cycle of evolution between
the cells and their newly synthesized ECM, forming a positive
feedback loop, which drives the progression of OA. In this
review, we will focus on the interplay between ECM and
cellular functions under inflammation, and how these factors
are responsible for the progression of OA. An understanding
of the complexity of the interplay between the cells and their
microenvironment may provide a sound basis for developing
suitable therapies to treat osteoarthritis.
2. Changes in Extracellular Matrix
Synthesis during Osteoarthritis
Progression of OA can be characterized by changes in ECM
composition and structure. Natural, healthy cartilage matrix
is mainly composed of collagen type II which provides
tensile support for the tissue. Aggrecan, a negatively charged
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proteoglycan that attracts watermolecules, provides the com-
pressive resistant and shock absorbing capability of cartilage
under loading [2]. It has been shown that during OA, there
are sequential events that affect the integrity of homeostatic
ECM; aggrecan content is decreased, while collagen content
is increased [2, 3, 5]. This change in ECM composition
predisposes the tissue for mechanical fault resulting in sig-
nificantly alteredmechanical environments of the cells within
the cartilage matrix.
In the initial stages of OA, proliferative chondrocytes
form clusters in order to adjust to the changing microenvi-
ronments [2]. This alteration of cellular configuration also
changes the quantity and composition of the ECM secreted
by the cells. It has been shown that there is a significant
downregulation of aggrecan gene expression at the onset
of OA in a rat model [1], and this finding agrees with
markedly low proteoglycan synthesis, observed in human
OA samples with normal appearance [6]. The changes of
aggrecan, which exists in a nonaggregated form in OA, alter
the permeability and thus mechanical compliance of the
matrix [2, 7]. The reduced proteoglycan content decreases
compressive modulus of cartilage and consequently exposes
the tissue to greater strains when exposed to mechanical
stress.
Unlike the decreased production of proteoglycan, col-
lagen synthesis rate increases in the early stages of OA
and remains elevated [8]. In addition to the increased ratio
of collagen/aggrecan synthesis, the composition of collagen
type has been also shown to change from collagen type
II to type I [9]. Healthy cartilage matrix mainly contains
collagen type II, while collagen type I is mainly found in
subchondral bone tissue [2, 3, 10]. The compositional change
affects the mechanical stability of the ECM network [10].
Compared to collagen type I, type II chains contain a higher
content of hydroxylysine as well as glucosyl and galactosyl
residues which mediate the interaction with proteoglycans
[11]. Therefore, the decreased collagen type II content during
OA inevitably undermines the integrity of ECM networks
formed by collagen and proteoglycan. Furthermore, Silver
et al. showed that the elastic modulus, due to shortened
collagen fibril lengths, decreases with an increased extent
of OA [12]. As a result of these changes, the osteoarthritic
cartilaginous tissues exhibit a reduced ability to store elastic
energy, and this, in turn, leads to fibrillation and fissure
formation [12]. Figure 1 shows the structural and compo-
sitional changes in cartilage in a monoiodoacetate- (MIA-)
induced arthritis model in rats. Although the animal model
induces significantly accelerated cartilage degeneration as
compared to typical human osteoarthritis, it depicts similar
structural and compositional changes in cartilage exhibited
in the pathogenesis of OA [13]. On day 11 post-MIA injection,
the overall cartilage damage was assessed at Grade 2-3
according to Osteoarthritis Research Society International’s
(OARSI’s) histopathology grading system showing cartilage
lesion formation, articular surface fissurization, subchondral
bone advancement, and bone marrow edema/cyst [14]. An
area exhibiting chondrocyte disorientation without vertical
fissure development was chosen to observe changes in car-
tilage matrix. In this area, nonchondrocytic collagen type I
is present in the cartilage matrix of the OA tissue, whereas
it is negligible in the control (Figure 1(B)). These changes
in the structure and composition of ECM progressively
alter the biological and mechanical microenvironments that
significantly modulate cellular activities as described later in
this review.
3. Inflammation-Induced Extracellular Matrix
Changes in Osteoarthritis
ECMchanges in cartilage can be attributed tomultiple factors
during the progression of OA. Among them, inflammation
plays an active role affecting both quantity and quality of
ECMs. Mechanical damage and/or age-related wear/tear are
thought to trigger systematic inflammatory responses in all
tissues surrounding the joint including articular cartilage,
synovial membrane, subchondral bone, and ligaments [2,
15]. Chondrocytes, the only cell type residing in cartilage,
respond to such inflammatory conditions and participate in
the catabolic activities that ultimately lead to the degradation
of cartilaginous ECM [16]. An animal model ofMIA-induced
arthritis showed that the sequential upregulation of inflam-
matory genes is associated with all levels of cartilage damage
throughout the progression of OA [1]. These upregulated
inflammatory genes form a positive feedback loop, mainly
through the NF-𝜅B signaling pathway, as the severity of the
cartilage damage progresses [17]. In fact, it was observed that
chondrocytes in human arthritic cartilages also constitutively
exhibit elevated activities of NF-𝜅B [18]. Factors that con-
tribute to the catabolic processes in OA include interleukin
1𝛽 (IL-1𝛽), tissue necrosis factor-𝛼 (TNF-𝛼), IL-12, IL-15, and
various associated chemokines [19–23]. These inflammatory
factors were shown to significantly increase the expression
of matrix degrading proteins including matrix metallopro-
teinases (MMPs) (i.e., MMP-1 and MMP-13) and various
types of a disintegrin and metalloproteinase with a throm-
bospondin type 1 motif (ADAMTS) (i.e., ADAMTS 1,4,5)
in chondrocytes [1, 24–30]. For example, an increase in cell
clustering, a typical morphological feature of chondrocytes
in the early stage of OA, was observed with an increase in
MMP-13 expression [31].The receptor for advanced glycation
end products (RAGE), which is increased in OA articular
chondrocytes, was also shown to stimulate MAP kinase
and NF-𝜅B activities that, in turn, increased the production
of MMP-13 and propagated the catabolism of the cartilage
matrix [32, 33].
The degenerative activities of matrix degrading proteins
are intensified by the elevated level of nitric oxide (NO), a
molecule which is also upregulated by inflammatory proteins
in chondrocytes. NO, upregulated by the transcriptional
activity of NF-𝜅B, perpetuates the chronic inflammation
that enhances matrix degradation and mediates apoptosis of
chondrocytes by creating oxidative environments [34–36]. In
a canine model of OA, the use of a NO inhibitor reduced the
degenerative changes in cartilage, possibly demonstrating the
critical role of NO in the progression of OA [34].
Concurrently with matrix degradation, the inflam-
mation-mediated downregulation of chondrogenic growth/
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Figure 1: Changes in the extracellular matrix structure and composition of cartilage afflicted by osteoarthritis (OA). Experimental OA was
induced by intra-articular injection ofmonoiodoacetate (MIA) similar to the previously described protocol using a ratmodel [4]. OA induced
rats were sacrificed at day 11, and the medial condyles of the arthritic knees (A (c-d); B (e–h)) were histologically (H&E staining (A)) and
immunohistologically (collagen type I (B (a) and (e)) and type II (Figure B (c) and (g)) compared to that of the saline-injected sham control
((A (a-b); B (a–d)). (A) Microscopic features of OA cartilage (grade 2-3) show cartilage lesion formation, articular surface fissurization,
subchondral bone advancement, and bone marrow edema/cyst. In addition, cell clustering and fibrocartilage formation is apparent in OA
samples. (A) (b and d) aremagnified images of the area indicated in (A) (a and c), respectively, to reveal the changes in cellularmorphology. (B)
Consecutive sections of the healthy and OA cartilages were stained using monoclonal antibodies for collagen type I or type II. An increase
in intensity for collagen type I is observed in the OA cartilage, while it is not present in the control cartilage. Collagen type II is readily
observed for both the healthy and OA cartilage. (B) (b, d, f, and h) are phase-contrast images of (B) (a, c, e, and g), respectively, to reveal tissue
morphologies.
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transcription factors that mediate chondrocytic ECM syn-
thesis, such as transforming growth factor 𝛽 (TGF-𝛽), sex
determining region Y-box 9 (SOX9), insulin-like growth
factor (IGF), and connective tissue growth factor (CTGF),
is also responsible for suppressing the anabolic activities of
chondrocytes [1, 37, 38]. Taken together, these results demon-
strate the significant influence of inflammatory mediators in
the progression of OA by altering the homeostasis of cartilage
ECM.
Another matrix component which is found in increased
concentrations in synovial fluid during OA is Tenascin-
C (TN-C), an ECM glycoprotein. Elevated levels of TN-C
have been suggested to induce inflammatory mediators and
promote ECM degradation in OA patients [39]. Although
TN-C is highly expressed during embryogenesis, its presence
is minimal in healthy adult tissues. Its expression during OA
is, however, highly upregulated [40, 41].The elevated concen-
tration of TN-C causes a significant effect in the catabolism
of the cartilage, resulting in degradation of ECM [39, 40].
Additionally, biglycan fragments in articular cartilage and
meniscus and fibronectin fragments in hip and knee synovia
have also been found in elevated levels as OA progresses
[42–44]. Both fragmented biglycan and fibronectin exhibit
proinflammatory effects through the activation of toll-like
receptors [45, 46]. Overall, the combination of inflammation-
induced upregulation of matrix-degrading proteins, down-
regulation of chondrocytic ECM synthesis, and accelerated
matrix degradation due to fragmented inflammatory ECMs,
promotes the progression of disease.
4. Alteration in Biomechanical
Environments during Osteoarthritis
The changes in altered ECM synthesis and elevated activ-
ities of matrix degrading proteins drastically change the
mechanical properties of cartilage, which further intensifies
the destructive processes associated with OA [47]. Initially,
an increase in cartilage thickness is observed by hyperpro-
liferative chondrocytes before noticeable surface fibrillation
occurs [48]. The highly proliferating chondrocytes produce
greater amount of aggrecan that leads to cartilage thickening
in dimensions as well as softening of extracellular matrix
[2]. At this stage, a lower shear modulus was observed in
the cartilage from an OA model when compared to normal
articular cartilage [49, 50]. In a mouse model, a reduction in
tensile stiffness in articular cartilage is also accompanied by
the tentative cartilage thickening [51]. These biomechanical
changes expose chondrocytes to an environment more sus-
ceptible to greater strains, as compared to physiological levels,
thus altering their cellular functions.
As the disease progresses, however, the tissue gradually
loses aggrecan content, which has provided compliance of
local mechanical environments due to its ability to interact
with watermolecules. In addition to aggrecan loss, it has been
recently shown that collagen fibril stiffens in osteoarthritic
cartilage [52]. Furthermore, another possible mechanism
through which the mechanical microenvironment changes is
the accumulation of advanced glycation end products (AGEs)
which can crosslink to the collagen network [53]. In vitro,
the increased AGE crosslinking to the collagen network was
shown to increase the stiffness of human adult articular
cartilage [53].The combination of aggrecan loss and collagen
network stiffening results in increased overall stiffness of
the tissue. Consequently, as OA advances, the cartilage layer
becomes thinner and stiffer transmitting greater load to the
underlying subchondral bones. The change in mechanical
conditions induces the advancement of subchondral bones
towards the articular surface leading to the development
of bone marrow edema/subchondral bone cysts and the
propagation of periarticular osteophytes [2, 54, 55]. Recent
studies suggest that these changes in subchondral bone
structure may precede the articular cartilage thinning [56].
Nevertheless, due to changes in the mechanical prop-
erties of the cartilage via altered homeostasis of ECM, its
residing cells, chondrocytes, are exposed to vastly different
biomechanical microenvironments that further intensify the
progression of OA by altering cellular behaviors. Ultimately,
this leads to the formation of fibrocartilaginous tissues that
exhibit more bone-like properties replacing the completely
degenerated cartilage in addition to osteophyte formation at
the periphery of the articular surface [2, 54].
5. The Effects of Inflammation on
Cartilage Extracellular Matrix Homeostasis
by Articular Chondrocytes
Global inflammation in synovium during OA affects chon-
drocytes that are responsible for ECM turnover and thus
cartilage homeostasis [57]. Inflammation which is persistent
in OA has shown to directly induce the catabolic activities
of chondrocytes. IL-1𝛽, a highly upregulated cytokine during
OA, has shown to induce upregulation of matrix degrading
enzymes such as MMP-1, 3, and 13 in chondrocytes [58].
Dozin et al. also showed that when exposed to inflammatory
cytokines, chondrocytes, regardless of patient age or OA
status of human donors, enhance their production of proin-
flammatory cytokines such as IL-6 and IL-8 [59]. TNF-𝛼,
another critical cytokine that is highly upregulated inOA, has
been shown to induceMMP-13 expression,mediated by ERK,
p38, JNK MAP kinases, and AP-1 and NF-𝜅B transcriptions
factors [24, 60, 61]. At the same time, the presence of
inflammatory cytokine IL-1𝛽 has been shown to play a
role in suppressed ECM synthesis through downregulation
of SOX9 [62]. This, in turn, decreases the expression of
collagen type II and aggrecan in articular chondrocytes. The
activation/suppression of such signaling cascades autoreg-
ulates chondrocytes to further upregulate the synthesis of
matrix degrading enzymes and downregulate the produc-
tion of chondrocytic ECMs [63]. Nitric oxide (NO) and
cyclooxygenase-2 (COX-2), two components which have
active roles in perpetuating inflammation, were also endoge-
nously expressed at high levels in chondrocytes from OA
tissues even when cultured in vitro in the absence of inflam-
matory cytokines [64, 65].These changes in metabolismmay
demonstrate a possible permanent phenotypical change in
the OA chondrocytes.
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In this regard, one notable alteration of chondrocytes in
arthritic joints is their production of nonchondrocytic ECM.
In addition to the increase in the production of collagen
type I replacing type II as previously described, chondrocytes
isolated from OA diseased tissues have shown to produce
collagen type X, a marker for hypertrophic chondrocytes, as
compared to undetectable expression of the protein in healthy
cartilage [66]. Collagen type X is typically synthesized by
hypertrophic chondrocytes that also produce collagen type I.
The emergence of these nonarticular chondrocytic proteins
may indicate the change of phenotype in chondrocytes as
the disease progresses. The morphological change of chon-
drocytes with abnormal nonround morphology in arthritic
cartilages could be related to a phenotypical change such as
an increase in IL-1𝛽 production and a decrease in pericellular
collagen type VI synthesis [67]. When the cells from arthritic
knees are subject to a chondrogenic in vitro culture condition,
they are not able to fully recover normal tissue phenotype as
evident by low cellularity and decreased chondrocytic ECM
production as compared to chondrocytes from healthy joints
[66, 67].This demonstrates that damages inOA cartilagemay
not be able to be fully recovered by autologous chondrocytes.
One possible cause of the phenotype change of OA
chondrocytes is inflammation as inflammatory synovial fluid
has shown to activate chondrocytes and dramatically affect
the normal processes of the cells.When healthy chondrocytes
are subjected to inflammation, simulated by inflammatory
cytokines such as IL-1𝛽, TNF-𝛼, CXCL1, or 8, all of which
are upregulated during OA, the cells exhibit hypertrophic
differentiation [68]. This differentiation is shown to be medi-
ated by RAGE signaling through the p38 MAPK pathway
[69]. Interestingly, the activation of the p38 MAPK signaling
pathway has also shown to promote the synthesis of MMP-
13 possibly linking the change in phenotype to the facilitated
rate of matrix turnover [32]. In addition to the synthe-
sis of nonchondrocytic ECM and enhancement in matrix
degradation, chronic inflammation also induces cell death.
When healthy chondrocytes were subject to synovial fluids
from osteoarthritic patients, the cells not only upregulated
the expression of cytokines, such as IL-6, IL-8, monocyte
chemotactic protein-1 (MCP-1), and vascular endothelial
growth factor (VEGF), but also underwent apoptosis [16].
6. The Effects of Changes in Extracellular
Matrix on Articular Chondrocytes
Thealteredmicroenvironments by ECM changes, in the pres-
ence of inflammation, further drive catabolic/nonreparative
activities of chondrocytes, ultimately leading to cartilage
destruction/achondrocytic ECM formation. As previously
described, themechanical properties of cartilage are dynami-
cally altered during the progression of OA due to imbalanced
matrix turnover (greater matrix degradation versus synthe-
sis) and noncartilaginous ECM formation. The increase in
local matrix stiffness due to changes in ECM appears to
suppress chondrocytic activities of the cells. Recent studies
show that chondrocytes sense the stiffness of the matrix
and differentially respond to it by altering their phenotype,
resulting in production of different types of ECM (i.e., ratio
of collagen type II to type I) [70–72]. An optimal stiffness
has been shown to promote greater SOX9, COL2A1, and
aggrecan gene expression in chondrocytes and either above
or below this stiffness induced dedifferentiation of the cells
towards fibrochondrocytic phenotype [70]. This effect of
matrix stiffness on modulating chondrogenic phenotype has
been shown to occur through the regulation of the TGF-
𝛽 signaling pathway [70]. In addition, the mechanosensitive
behavior of chondrocytes may explain the fact that typical in
vitro 2D culture of chondrocytes on stiff tissue culture plastics
results in the dedifferentiation of the cells [73–75].
The changes in matrix composition during OA not only
affect the mechanical environments of chondrocytes but
also alter interactions of matrix proteins with the cells.
Matrilin-3 (MATN3) is a matrix protein that is highly
upregulated during OA [76, 77]. Although the protein is a
part of healthy cartilage matrix, the soluble form of MATN3
is upregulated and released to synovial fluid in OA [78].
When human chondrocytes were cultured in the presence
of soluble MATN3, there was a decrease in ECM anabolism
and increased catabolism only at concentrations higher than
those found in OA patients. On the other hand, when soluble
MATN3 was immobilized, ECM synthesis and accumulation
was enhanced [78].These results show howMATN3, which is
found in synovial fluid of OA patients, can change the behav-
ior of chondrocytes, demonstrating the direct involvement
of ECM in the progression of OA by interacting with the
cells as well as indirectly by changing the cells’ mechanical
environments.
The presence of calcium crystals in cartilage has been
shown to increase with severity of OA, and these changes
have a strong correlation with hypertrophic chondrocyte dif-
ferentiation [79]. Interestingly, bovine articular chondrocytes
within cartilage explants, when exposed to basic calcium
phosphate crystals, had significant increases in intracellular
calcium content, which is correlated with cartilage matrix
degradation [80]. Another ECM component that affects
chondrocyte metabolism is fibronectin, which showed a
significant positive correlation between chondrocyte apop-
tosis and fibronectin content [81]. Overall, these multi-
faceted effects by changes in ECM, including dysregulation of
matrix synthesis (reduction in collagen type II and aggrecan,
increase in collagen type I and X), upregulation of matrix
degradation, and induction of cell apoptosis, promote the
progression of OA by altering the cellular behaviors of
chondrocytes.
7. The Effects of Inflammation
on Chondrogenic Differentiation
of Mesenchymal Stem
Cells during Osteoarthritis
The mechanisms involving the initiation of OA are still
elusive as some argue it is mechanical damage-induced and
others inflammation-induced. Nevertheless, once the disease
is initiated, the degeneration of cartilage matrix progresses
due to the combination of chronic inflammation and altered
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mechanical loading as discussed earlier. A part of the pro-
gressive degenerative processes is due to the limited regen-
erative capability of chondrocytes. These cells are typically
quiescent in healthy cartilage [2]. When they are exposed
to proliferating conditions to repair the cartilage damage,
they often dedifferentiate to a phenotype that produces
nonchondrocytic ECM [2]. This atypical ECM synthesis
further drives chondrocyte dedifferentiation and nonhome-
ostatic ECM synthesis by altered mechanical environments.
In addition to chondrocytes, the repair of the damaged tissue
is attempted by another cell type, mesenchymal stem cell
(MSC), that can differentiate to all mesenchymal lineage
cells including chondrocyte, osteoblast, and adipocyte [82].
MSCs often participate in the repair of bone damage since
they constitute bone marrow. Due to its close proximity
to the cartilage layer in the subchondral marrow and their
ability to differentiate into chondrocytes, MSCs have been
considered as a possible cell source involved in cartilage
repair.
For this reason, microfracture (or microperforation)
surgery is often used to treat a localized cartilage lesion.
Small fractures are created in the subchondral bone, and this
causes new cartilage formationmainly due to the regenerative
activities of MSCs from the bone marrow [83]. Although
this technique has shown some benefits repairing damaged
cartilage, the neotissue contains fibrocartilage that exhibits
different mechanical properties, leading to question its long-
term stability [84, 85]. These studies may provide clues for
why endogenousMSCs cannot fully rescue damaged cartilage
during the progression of osteoarthritis, unlike the positive
healing response after bone fractures. Typically, subchondral
bone advances towards the cartilage surface as the articular
surface degrades [86]. In this condition, MSCs are subjected
to a milieu of inflammation, altered ECM composition, and
vastly different mechanical loading profiles in the injured
cartilage, all of which affect the differentiation of MSCs to
chondrocytes.
As described earlier, the native cartilage is exposed
to chronic inflammation conditions by increased levels
of inflammatory mediators including IL-1𝛽, TNF-𝛼, and
prostaglandin E
2
(PGE
2
) [87, 88]. These inflammatory
cytokines not only affect the homeostatic functions of res-
idential chondrocytes but also impact the chondrogenic
differentiation of MSCs [87, 89–91]. Treatment of IL-1𝛽
during chondrogenic differentiation of bonemarrow-derived
MSCs suppresses Sox9 expression, a critical transcription
factor that controls chondrogenesis [90]. The suppression of
Sox9 subsequently leads to a decrease in collagen type II
and aggrecan expression. In addition, TNF-𝛼, in combina-
tion with IL-1𝛽, has been shown to transform embryonic
chondroprogenitor cells into fibroblast-like cells, further
suggesting the inhibitory effects of inflammatory cytokines
on chondrogenesis [87]. Similarly, when human MSCs are
exposed to conditioned medium derived from osteoarthritic
synovium, chondrogenesis is inhibited [92]. These antichon-
drogenic effects of inflammatory cytokines were shown to be
caused by the activation of the NF-𝜅B signaling pathway [93].
Overall, inflammatory conditions present in OA cartilage
prevent chondrocytic differentiation ofMSCs, thus inhibiting
regeneration of damaged cartilage with appropriate chondro-
cytic ECMs.
8. The Effects of Changes in Extracellular
Matrix on Chondrocytic Differentiation
of Mesenchymal Stem Cell
The changes in the composition of ECM also affect chon-
drogenic differentiation of MSCs. In a study by Bosnakovski
et al., MSCs cultured in collagen type II hydrogels exhibited
greater gene expression levels of chondrocytic markers as
compared to those cultured on typical tissue culture plates
[94]. As OA progresses, residential chondrocytes start to
produce collagen type I instead of type II. This change can
affect the subsequent chondrogenesis of MSCs as it has been
shown that collagen type II favors chondrogenic induction by
modulating cell shape, as compared to collagen type I [95].
It was demonstrated that collagen type II promotes a more
rounded cell shape, similar to that of the native chondrocyte
in healthy cartilage, through the 𝛽1 integrin-mediated Rho
A/Rock signaling pathway.
In addition to the compositional effect, mechanical
changes of ECMs (become stiffer due to the loss of hydrating
aggrecan inOA) affect chondrogenesis ofMSCs by regulating
cell morphology [96]. A softer mechanical environment
enhances chondrogenesis of MSCs, evident by greater gene
and protein expression of chondrogenic markers including
SOX9, collagen type II, and aggrecan by inhibiting stress fiber
formation, as compared to the stiffer environment. Similarly,
using polyacrylamide hydrogels with varying stiffnesses,
Xue et al. showed that human mesenchymal stem cells are
differentiated towards a chondrocytic phenotype on softer
gels, regardless of initial cell seeding density [97]. The study
highlights the importance of cell-matrix interactions during
chondrogenic differentiation of MSCs.
Along with the direct influence of local stiffness change
onMSCdifferentiation, the alteredmechanical profiles under
loading also affect the differentiation process. Bone marrow
derived MSCs seeded onto fibrin hydrogels developed a
spread out morphology and differentiated towards a myo-
genic lineage [98]. In the presence of long-term, dynamic
compression, myogenic differentiation was inhibited, while
markers for chondrogenic phenotype were upregulated.
However, the magnitude of loading is an important factor
determining chondrocytic differentiation of MSCs and thus
synthesis of proper ECMs. Under the same loading regimen,
a stiffer ECM induces less strain on the cells. In this regard,
Michalopoulos et al. have recently shown that physiological
compressive loading (15% strain) on MSC-laden scaffolds
induces greater chondrogenesis as compared to a smaller
strain of 10% that led to greater osteogenesis [99]. Similarly,
stiffer agarose gels inhibited cartilage matrix production
and gene expression of MSCs under hydrostatic pressure as
compared to those in softer microenvironments [100]. These
studies demonstrate that changes in the mechanical proper-
ties of cartilage during OA may favor the differentiation of
MSCs towards nonchondrocytic lineages further intensifying
the degeneration of cartilage. Overall, altered environments
BioMed Research International 7
Inflammation
mechanical defect
Mesenchymal
stem cells
OA Articular 
chondrocytes
OA
OA
Nonchondrocytic
ECM
Progression of OA
Figure 2: Schematic of the interplay between the extracellular matrix and cellular activities under inflammation during the progression of
osteoarthritis (OA). Wear and tear or trauma induces inflammation and mechanical defects in cartilage, which initiate OA. These altered
microenvironments affect the residential chondrocytes to produce nonchondrocytic extracellular matrix (ECM) that, in turn, further drives
the dedifferentiation of the chondrocytes. The changes in microenvironments also negatively affect the chondrogenic differentiation of
mesenchymal stem cells that originate from subchondral bone marrow, preventing the self-regeneration of cartilage. The positive feedback
loop between mal-formed ECM and cellular activities drives the progression of OA.
in ECM composition and mechanical properties during the
progression of OA significantly limit the chondrogenesis
of MSCs inhibiting the regeneration process of cartilage
damage.
9. Summary
Both inflammatory factors and compositional/structural
changes of ECM drive the progression of OA by affecting
residential articular chondrocytes as well as MSCs that
migrate from bone marrow in the underlying subchondral
bone to repair the cartilage defect (Figure 2). Due to chronic
inflammation and altered microenvironments, chondrocytes
change their phenotype towards more hypertrophic cells
resulting in achondrocytic ECM synthesis. These changes
in ECM, in combination with cartilage matrix degradation
under inflammation, further fuel the degeneration process
resulting in the alteration of biomechanical conditions, which
disturb the surrounding tissues in the joint.TheECMchanges
in the presence of inflammation also negatively affect chon-
drogenic differentiation of MSCs, limiting self-regeneration
of cartilage. Overall, the interplay between changes in ECM
and changes in cellular function under inflammation forms a
positive feedback loop that drives the pathology of OA.
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